New immune cell therapy tested for Tough-to-Treat brain cancer
NCT ID NCT06355908
Summary
This early-stage trial is testing the safety and initial effects of a new type of CAR-T cell therapy for adults with aggressive brain tumors (grade 4 glioma) that have returned or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to target a specific protein (IL13Ra2) found on these tumor cells. The study aims to find a safe dose and see if this approach can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.